New biomarkers for diagnosis and treatment monitoring for anemia and/or systemic iron overload in a patient suffering from a myeloid malignancy

The invention relates to the domain of anemia, iron overload and myeloid malignancy. The inventors identify a variant transcript of ERFE specific of SF3B1MUT MDS that contributes to increased concentration of ERFE protein leading to hepcidin suppression and iron accumulation in patients. This transcript contains an in-frame added intronic sequence of 12 nucleotides not inducing a stop codon that may be translated into a variant protein with an additional 4 amino acids. By using deep mass spectrometry, they identified a peptide corresponding to the added polypeptide VPQF (SEQ ID NO: 5) demonstrating the active production of a variant protein by bone marrow erythroblasts of patients with a SF3B1-mutated MDS. This variant can be used as a pertinent biomarker of clonal erythropoiesis for monitoring treatments of anemia in SF3B1MUT patients. Thus, the invention relates to a variant of the transcript of ERFE and its use in diagnosing and monitoring of anemia and iron overload in patient with a myeloid malignancy with at least one mutation in the SF3B1 gene.

Keywords: ELISA, PCR, RT-PCR, Genomics, Immunoassay, Transcriptomics, Diagnostic, Risk Prediction, Treatment Response in Anemia, Systemic iron overload, Parenchymal iron overload, myeloid malignancies, Myelodysplastic syndromes
Patent Application number: European Procedure (Patents) (EPA) - 16 Janv. 2019 - 19 305 047.3
Inventors:
FONTENAY MichaelaALSAFADI SamarSTERN Marc-henriHOUY AlexandreKAUTZ LéonGUILLONNEAU FrançoisLEFEVRE CarineKOSMIDER Olivier

Reference:

BIO18095-D1

    Business Developper
    contact
    Inserm Transfert
    Business Developer
    Patent filling date: 16-01-2019
    Rare disease: No
    Second indication: No

    You might also be interested in